BeiGene
BGNE
#881
Rank
โ‚ฌ20.01 B
Marketcap
182,28ย โ‚ฌ
Share price
1.71%
Change (1 day)
0.79%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total assets

Total assets on the balance sheet as of June 2024 : โ‚ฌ5.15 B

According to BeiGene 's latest financial reports the company's total assets are โ‚ฌ5.15 B. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

BeiGene - Total assets on balance sheet (from 2014 to 2024)

Total assets by year

Year Total assets Change
2023-12-31โ‚ฌ5.25 B-11.7%
2022-12-31โ‚ฌ5.94 B-20.73%
2021-12-31โ‚ฌ7.50 B63.75%
2020-12-31โ‚ฌ4.58 B219.08%
2019-12-31โ‚ฌ1.43 B-26.88%
2018-12-31โ‚ฌ1.96 B125.17%
2017-12-31โ‚ฌ0.87 B126.06%
2016-12-31โ‚ฌ0.38 B260.72%
2015-12-31โ‚ฌ0.10 B142.81%
2014-12-31โ‚ฌ44.04 M415.8%
2013-12-31โ‚ฌ8.53 M

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
โ‚ฌ16.39 M-99.68%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ1.78 B-65.34%๐Ÿ‡บ๐Ÿ‡ธ USA